Dr. Gomella on the Role of Genetic Testing in Prostate Cancer

Video

In Partnership With:

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the role of genetic testing in prostate cancer.

The role of genetic testing has grown significantly in prostate cancer and urology, Gomella says. Moreover, the field continues to provide data that suggest prostate cancer is driven by germline genetic alterations. As such, genetic testing is now incorporated into the National Comprehensive Cancer Network guidelines with regard to screening and treatment, Gomella explains.

Currently, the guidelines state that patients who present with metastatic prostate cancer, patients who develop metastatic castration-resistant prostate cancer, or patients with a family history of inheritable cancers, including prostate, breast, pancreatic, gastrointestinal and ovarian cancers, as well as melanoma, should undergo germline genetic testing, Gomella concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,